Analyzing Neos Therapeutics (NEOS) & Amicus Therapeutics (FOLD)

Neos Therapeutics (NASDAQ:NEOS) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Analyst Ratings

This is a breakdown of current recommendations for Neos Therapeutics and Amicus Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neos Therapeutics 0 1 3 0 2.75
Amicus Therapeutics 0 1 3 0 2.75

Neos Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 260.47%. Amicus Therapeutics has a consensus target price of $20.25, indicating a potential upside of 50.67%. Given Neos Therapeutics’ higher probable upside, research analysts plainly believe Neos Therapeutics is more favorable than Amicus Therapeutics.

Risk & Volatility

Neos Therapeutics has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Valuation and Earnings

This table compares Neos Therapeutics and Amicus Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neos Therapeutics $25.02 million 5.10 -$66.24 million ($2.68) -1.60
Amicus Therapeutics $36.93 million 68.83 -$284.00 million ($2.92) -4.60

Neos Therapeutics has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Neos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

47.5% of Neos Therapeutics shares are held by institutional investors. 5.4% of Neos Therapeutics shares are held by insiders. Comparatively, 2.9% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Neos Therapeutics and Amicus Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neos Therapeutics -164.40% -586.25% -59.85%
Amicus Therapeutics -460.04% -53.45% -32.85%

Summary

Neos Therapeutics beats Amicus Therapeutics on 7 of the 12 factors compared between the two stocks.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply